Janumet (Sitagliptin Metformin HCL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 28, 2017 Category: Drugs & Pharmacology Source Type: news

Juvisync (Sitagliptin and Simvastatin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 21, 2017 Category: Drugs & Pharmacology Source Type: news

Fewer T2D Patients Advanced Therapy With GLP-1 Pump
(MedPage Today) -- Less need for additional drugs with implantable exenatide versus sitagliptin, placebo (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 12, 2017 Category: Primary Care Source Type: news

Why Did the FDA Refuse to Add TECOS Data to Sitagliptin Label? Why Did the FDA Refuse to Add TECOS Data to Sitagliptin Label?
Although it ' s not clear exactly what Merck was requesting when it asked the FDA to add the TECOS data to the label for its type 2 diabetes drug, the recent refusal of the agency to do so is mystifying.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Merck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA ® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the American Diabetes Association
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that 19 scientific presentations from Merck ’s diabetes pipeline and portfolio – including Phase 3 data for investigational ertugliflozin, additional analyses of JANUVIA® (sitagliptin), and real-world research – will be presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) in San Diego, June 9-13, 2017.Language: EnglishContact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-740-6179o...
Source: Merck.com - Product News - May 16, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

TECOS: Sitagliptin Safe in CKD Patients (CME/CE)
(MedPage Today) -- Sub-analysis in patients with chronic kidney disease and T2DM raised no safety concerns (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 26, 2017 Category: Cardiology Source Type: news

FDA Turns Down Sitagliptin Heart Data for Drug Label
(MedPage Today) -- TECOS results apparently not good enough to warrant new claim (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 7, 2017 Category: Urology & Nephrology Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck ’s Supplemental New Drug Applications for JANUVIA®(sitagliptin), JANUMET® (sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin and metformin HCl extended-release).Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExcha...
Source: Merck.com - Corporate News - April 7, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories. (Source: World Pharma News)
Source: World Pharma News - April 3, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes
Dateline City: KENILWORTH, N.J.& NEW YORK Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or MetforminKENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S.Language: EnglishContact: Merck Media:Doris Li, (908) 246-5701orMerck Investor:Amy Klug, (908) 740-1898orKristen Drake, (908) 236-4223orPfizer Media:Steve Danehy, (212) 733-1538orPfizer Investor:Ryan Crowe, (212) 733-8160Ticker Slug:Ticker:MRK...
Source: Merck.com - Research and Development News - March 6, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK #Pfizer $MRK $PFE Januvia MSD NYSE:MRK Source Type: news

Study Finds No Safety Concerns for Sitagliptin Use in Elderly Study Finds No Safety Concerns for Sitagliptin Use in Elderly
Sitagliptin does not appear to increase the risk of cardiovascular events in patients with type 2 diabetes who are 75 years or older, according to results from the TECOS trial. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 3, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Janumet XR (Sitagliptin and Metformin HCl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2017 Category: Drugs & Pharmacology Source Type: news

Sitagliptin Insulin Evaluated in Hospitalized T2D Patients (CME/CE)
(MedPage Today) -- Combination proved non-inferior to standard basal-bolus insulin treatment (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - December 15, 2016 Category: Consumer Health News Source Type: news

The Year In Review: Merck Can Look Back And Smile
Merck has had a reasonably good year. The company saw a turn-around in its business on the back of its relatively new cancer drug, Keytruda. The anti-infectives division sustained itself, with key metabolism drugs Januvia and Janumet gradually inching up. In fact, the competitive pressure from J&J ’s Invokana, which threatened [...] (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 13, 2016 Category: Pharmaceuticals Authors: Trefis Team, Contributor Tags: NYSE:MRK Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news